Figure 3. Ruxolitinib treatment induces increase in miR-543 levels when miR-543 and JAK2^V617F mutation are present.

(A) Expression of miR-543 after treatment with ruxolitinib measured by RT-qPCR in K562 cells and OCI-AML3 cells stably transfected with empty vector (control) or p–miR-543 expression vector. U6 and RNU48 levels were used as normalizers. (B) Expression of miR-543 after treatment with ruxolitinib measured by RT-qPCR in J53Z1 cells containing the JAK2^V617F mutation. U6 and RNU48 levels were used as normalizers. Comparisons were made using 2-tailed t test or Mann-Whitney-Wilcoxon nonparametric test. All experiments were repeated independently 3 times, and representative blots are shown.